Placenta-derived stem cells may help treat lung diseases
July 28th, 2009 - 1:40 pm ICT by ANIWashington, July 28 (ANI): A new research, conducted by Italian boffins, has shown that stem cells derived from human placenta could help in the treatment of lung diseases, such as pulmonary fibrosis and fibrotic diseases caused by tuberculosis, chemical exposure, radiation or pathogens.
These diseases can eventually lead to loss of normal lung tissue and organ failure. No known therapy effectively reverses or stops the fibrotic process.
Stem cells derived from placenta are known to be able to engraft in solid organs, including the lungs. Human term placenta stem cells also show characteristics of high plasticity and low immunogenicity.
“The potential application of foetal membrane-derived cells as a therapeutic tool for disorders characterized by inflammation and fibrosis is supported in previous studies,” says study’s lead author Dr. Ornella Parolini.
“In line with the hypothesis that cells derived from the amniotic membrane have immunomodulatory properties and have been used as an anti-inflammatory agent, we set out to evaluate the effects of fetal membrane-derived cell transplantation in chemically-treated (bleomycin) mice,” Parolini added.
According to Parolini, cells delivered via intra-peritoneal transplant, regardless of the cells being allogenic or xenogenic (host’s own cells or from another individual respectively), the procedure resulted in a significant anti-fibrotic effect on the lab animals.
Parolini says that a “consistent” reduction in lung fibrosis “provides convincing proof” that placenta-derived cells do confer benefits for bleomycin-induced lung injury.
While the severity of inflammation did not show an overall reduction, there was a marked reduction in neutrophil (white blood cell) infiltration after both xeno-and-allo-transplantation.
“It is worth noting that the presence of neutrophils is associated with poor prognosis for several lung diseases. However, the mechanism by which placenta-derived cells might affect infiltration by neutrophils is not known,” says Parolini.
The researchers speculated that these cells might produce soluble factors that induce anti-inflammatory effects.
“Our findings suggest that fetal membrane-derived cells may prove useful for cell therapy of fibrotic diseases in the future,” says Parolini.
The study has been published in the current issue of Cell Transplantation. (ANI)
- New way to halt lung inflammation in animal models discovered - Jan 15, 2011
- New study offers hope to those with Alzheimer's, ALS - Mar 08, 2011
- Cholesterol regulator plays key role in development of liver fibrosis - Mar 31, 2011
- Umbilical cord blood stem cell transplant may help patients with lung, heart disorders - Nov 24, 2009
- Human placenta stem cells show therapeutic potential in stroke models - Feb 02, 2011
- Stem cell transplants show promise for patients with kidney problems - Feb 15, 2011
- Cigarette smoke may cause inflammation through a new chemical pathway - Sep 03, 2010
- Infliximab treatment effective for cystic fibrosis and Crohn's disease - Apr 20, 2010
- Tumeric derivative found promising in tendinitis - Aug 11, 2011
- Finding paves way for new personalized treatments to target inflammation - Apr 05, 2011
- Mums' stem cells could be key to treating genetic disease before birth - Jan 19, 2011
- Purple periwinkles may help fight inflammatory diseases - May 04, 2010
- Scientists turn stem cells into intestinal tissue for the first time - Dec 13, 2010
- Stem cells may help treat aggressive multiple sclerosis - Mar 22, 2011
- Novel drug may benefit cystic fibrosis patients - Dec 18, 2010
Tags: amniotic membrane, bleomycin, boffins, cell transplantation, convincing proof, fetal membrane, fibrotic, human placenta, immunomodulatory properties, inflammatory agent, lab animals, lung diseases, lung fibrosis, lung injury, organ failure, poor prognosis, pulmonary fibrosis, stem cells, therapeutic tool, white blood cell